Why Two Health Systems Ran the Same Readmission Program and Got Opposite Results
Here's a thing that should bother every health system executive who's ever signed off on a patient outreach budget.
Two large studies. Same basic idea: reach out to patients after discharge, automatically, to keep them out of the hospital. One worked. One didn't. And the difference between them is the whole ballgame.
I'm going to walk you through both, because if you're a CMO or a VP of population health staring at a vendor pitch right now, the gap between these two results is exactly the trap you're trying to avoid.
What happened in the study that worked?
A heart failure outreach program reduced 30-day all-cause readmissions, and it did it without an app or a portal login. Patients got near-daily texts and emails after discharge. Short educational videos. Symptom surveys. Weight reminders. One question carried unusual weight: are you worried your health might send you to the ER? If yes, the system asked if they wanted to be connected to clinical staff. A second yes routed them straight to a nurse or the after-hours line.
The program was fully automated until the moment a human was actually needed. Each readmission it prevented saved a payer between $15,000 and $20,000. Patients reported high satisfaction. Providers loved it, because they only got pulled in when their expertise genuinely mattered.
So far this sounds like every outreach pitch you've ever heard. Now the other one.
Why did the other readmission program fail?
A different trial, one of the largest post-discharge mHealth studies ever run, sent automated SMS messages to patients for 30 days after discharge alongside standard care. The result, published in JMIR this year, was blunt. No significant reduction in readmissions.
Same category of intervention. Opposite outcome.
The researchers dug into why. The answer is uncomfortable. Most patients in the intervention arm barely used the thing. A minority engaged with the platform before they ended up back in the hospital. The authors put it plainly: the presence of an outreach program alone may be insufficient to reduce revisits without sufficient patient engagement.
Read that again if you're about to buy something. The program existed. The patients didn't engage. So nothing changed.
So is the lesson "automation doesn't work"?
No. The lesson is that automation is not the product. Engagement is the product.
I learned this the hard way and it cost me a year. I built a mental health app once. Polished, clever, the works. Fifteen percent of patients used it. I had confused "we shipped a tool" with "patients are getting care." Those are not the same sentence. They're not even the same language.
When I stopped making people come to a screen and instead had an AI voice call them, engagement went to 85%. Not because the AI was smarter. Because a phone call meets a person where they already are. They don't have to download anything, remember a password, or develop a new habit at the worst moment of their lives. The channel was the intervention.
That's the difference between the two studies. The one that worked pushed to the patient, on channels they already used, with a dead-simple path to a human. The one that failed waited for the patient to come engage, and most of them didn't.
What does this mean for a health system buying outreach at scale?
It means you should stop evaluating these tools on features and start evaluating them on engagement rates. Period.
A vendor will show you a dashboard with forty capabilities. EHR write-back, multi-channel, SMS cascades, the lot. None of that matters if the patient ignores it. The only metric that predicts whether you'll move your readmission numbers is: what percentage of your actual patients actually respond? Most of the market sits at the 15 to 20% baseline that the failed trial lived in. HANA runs at 85% weekly engagement, and that single number is why the downstream outcomes show up at all.
Ask every vendor for their engagement rate by channel, in production, with real patients. If they dodge, you have your answer. The economics only work if patients pick up. You can run the readmission math yourself against our pricing model once you know your own engagement assumption.
How do you avoid buying the program that doesn't move the needle?
Demand proof of engagement before proof of features, and make sure there's a clean route from automated contact to a real clinician.
The study that worked had two things the failed one didn't. High engagement, because it pushed to patients instead of waiting for them. And a tight, obvious escalation path, two yeses and you're talking to a nurse. A separate analysis of post-discharge follow-up programs makes the same point: the agent's job is to keep the patient connected to the clinician and to recognize when something needs human attention, not to replace the human. The handoff is the safety net. We documented how that escalation routing is wired in our integration docs, because if you get that wrong, engagement won't save you.
One more thing. HANA has run over a million patient interactions with zero critical adverse events, across five countries and three languages, fully open-source and self-hosted. The scale isn't the brag. The brag is that the escalation logic held the whole way up.
Key Takeaways
Two readmission programs, same premise, opposite results, and the variable that explains the gap is engagement. The program that pushed daily to patients on channels they already used, with a simple path to a human, reduced 30-day readmissions and saved $15,000 to $20,000 per avoided readmission. The program that waited for patients to engage with an SMS platform saw no significant reduction, because most patients never engaged.
If you're buying patient outreach at scale, the takeaway is to invert your evaluation. Engagement first, features second. A tool with forty features and 15% engagement will lose to a tool with one job and 85% engagement, every time. And whatever you buy, make sure the handoff to a clinician is fast and unmissable, because automation without escalation is a liability, not a safety net.
If you want help pressure-testing a vendor's engagement claims against your own patient population, book a discovery call with me and we'll go through the questions to ask.
FAQ
Why do so many patient outreach programs fail to reduce readmissions?
Usually because patients don't engage. The JMIR analysis found that an automated SMS program produced no significant readmission reduction largely because only a minority of patients used it. The intervention existed but didn't reach people, so outcomes didn't move. Engagement, not the presence of a program, is what drives results.
What engagement rate should a health system expect from patient outreach?
The industry baseline sits around 15 to 20%, which is the range where programs tend to fail to move readmissions. Programs that push to patients on familiar channels, like a phone call, can reach far higher. HANA operates at roughly 85% weekly engagement, and that order-of-magnitude difference is what separates programs that change outcomes from ones that don't.
Does AI outreach replace clinical staff in post-discharge care?
No. The most effective programs automate the routine check-ins and reserve human clinicians for the moments that need judgment. A clear, fast escalation path from the automated agent to a nurse is what makes the model safe, and it's also what providers in the successful studies valued most, since they were only pulled in when it mattered.